Biopharma Middle East & Africa (Biopharma-MEA) Company Profile

Background

Biopharma Middle East & Africa (Biopharma-MEA) is a Dubai-based pharmaceutical company specializing in the marketing and sales promotion of niche and biotech pharmaceutical products across the Middle East region. Established in 2007 by Sh. Yasser Naghi and Dr. Mohamed Ramzy, Biopharma-MEA operates as an affiliate of the Cigalah Group, a leading Saudi pharmaceutical distributor representing over 30 pharmaceutical companies in Saudi Arabia. The company's mission is to enhance patient care by introducing innovative therapies to the Middle Eastern medical landscape, particularly in the field of pioneering biotech pharmaceutical products.

Key Strategic Focus

Biopharma-MEA focuses on providing efficient market access for multinational pharmaceutical companies to the Middle East markets, especially for pioneering biotech pharmaceutical products. The company collaborates with local distributors in each market for logistic activities, ensuring the availability and reimbursement needed for patients to benefit directly from these therapies. Biopharma-MEA has successfully introduced various new products to different countries across the Middle East, securing reliable market access for these introductions.

Financials and Funding

As of the latest available data, Biopharma-MEA has an estimated revenue of $17 million and employs approximately 78 individuals. The company has experienced significant growth under the leadership of General Manager Tamer Eissa, with total turnover exceeding $140 million.

Pipeline Development

Biopharma-MEA has successfully introduced many "New to Market" and "New in Class" products to the Middle East markets. These introductions have been done in full coordination with their partners, achieving numerous successes and shaping the future of many existing therapeutic areas.

Technological Platform and Innovation

Biopharma-MEA specializes in the marketing and sales promotion of niche and biotech pharmaceutical products. The company collaborates with local distributors in each market for logistic activities, ensuring the availability and reimbursement needed for patients to benefit directly from these therapies.

Leadership Team

Dr. Mohamed Ramzy, Chief Executive Officer

Co-founder of Biopharma-MEA in 2007. Under his leadership, the company has successfully introduced various new products to different countries across the Middle East.

Tamer Eissa, General Manager

Joined Biopharma-MEA in October 2008 as Sales Director and was promoted to General Manager in 2013. He has over 15 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the total turnover of Biopharma-MEA exceeded $140 million.

Leadership Changes

There have been no recent significant changes or appointments within the company's leadership team.

Competitor Profile

Market Insights and Dynamics

The biopharmaceutical market in the Middle East & Africa is projected to reach $12,446.1 million by 2030, growing at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2030. The biopharmaceuticals contract manufacturing market in the region is expected to reach $1,761.3 million by 2030, with a CAGR of 11.2% from 2025 to 2030.

Competitor Analysis

Key competitors in the Middle East & Africa biopharmaceutical market include:

Boehringer Ingelheim: A global pharmaceutical company with a strong presence in the region.

Lonza Group Ltd: A leading contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry.

Innovent Biologics Inc: A biopharmaceutical company specializing in the development of innovative therapies.

Rentschler Biopharma SE: A CDMO focused on the development and manufacturing of biopharmaceuticals.

JRS Pharma: A manufacturer of excipients and functional ingredients for the pharmaceutical industry.

AGC Inc: A global company offering contract manufacturing services for biopharmaceuticals.

AGC Biologics: A CDMO specializing in the development and manufacturing of biopharmaceuticals.

Probiogen: A biotechnology company offering cell line development and manufacturing services.

FUJIFILM Holdings Corp: A diversified company with a biopharmaceutical contract manufacturing division.

Toyobo Co Ltd: A company involved in the biopharmaceutical contract manufacturing market.

Samsung Electronics Co Ltd: Through its subsidiary Samsung Biologics, it offers biopharmaceutical contract manufacturing services.

Thermo Fisher Scientific Inc: A global company providing services to the biopharmaceutical industry.

WuXi Biologics (Cayman) Inc: A global open-access biologics technology platform offering end-to-end solutions.

AbbVie Inc: A global biopharmaceutical company with a presence in the region.

Novartis AG ADR: A global healthcare company with a biopharmaceutical division.

Catalent Inc: A global provider of advanced delivery technologies and development solutions for drugs.

ADMA Biologics Inc: A biopharmaceutical company specializing in the development and manufacturing of plasma-derived products.

Pfizer Inc: A global biopharmaceutical company with a strong presence in the region.

Siegfried Holding AG: A global CDMO serving the biopharmaceutical industry.

Cambrex: A global CDMO specializing in small molecule active pharmaceutical ingredients.

Binex: A biopharmaceutical company involved in contract manufacturing.

Strategic Collaborations and Partnerships

In August 2024, Biopharma-MEA entered into an exclusive agreement with LEO Pharma to commercialize the Thrombosis Portfolio in Saudi Arabia. This collaboration aims to enhance patient care by addressing the need for treatment options in the field of thrombosis.

Operational Insights

Biopharma-MEA's strategic focus on niche and biotech pharmaceutical products, combined with its collaborations with local distributors, positions the company to effectively navigate the competitive landscape in the Middle East & Africa biopharmaceutical market. The company's commitment to integrity, excellence, accountability, ownership, respect, and teamwork underpins its operations and market approach.

Strategic Opportunities and Future Directions

Biopharma-MEA is committed to improving the lives of patients in the Middle East by introducing new and exciting products for conditions with currently unsolvable medical needs. The company supports patients throughout their journey from diagnosis to treatment, developing partnerships with patient support programs across local health and social communities. Biopharma-MEA's innovative projects and partnering programs are well appreciated by both patients and medical professionals, with some projects being implemented on a national level in key Middle East markets.